{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T05:21:28Z","timestamp":1774675288149,"version":"3.50.1"},"reference-count":13,"publisher":"Kurume Medical Journal","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2022,12,31]]},"DOI":"10.2739\/kurumemedj.ms6934008","type":"journal-article","created":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T22:11:20Z","timestamp":1705356680000},"page":"255-259","source":"Crossref","is-referenced-by-count":3,"title":["Onasemnogene Abeparvovec Treatment after Nusinersen in an Infant with Spinal Muscular Atrophy Type 1"],"prefix":"10.2739","volume":"69","author":[{"given":"DAIKI","family":"NANRI","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOTARO","family":"YUGE","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KOHEI","family":"GOTO","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKURO","family":"KIMURA","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUKAKO","family":"YAE","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TATSUKI","family":"MIZUOCHI","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RYOSUKE","family":"SATO","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oita University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOYO","family":"ITONAGA","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oita University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TOMOKI","family":"MAEDA","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Oita University Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YUSHIRO","family":"YAMASHITA","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Health, Kurume University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sugarman EA, Nagan N, Zhu H, Akmaev VR, Zhou Z et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet 2012; 20:27-32.","DOI":"10.1038\/ejhg.2011.134"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014; 83:810-817.","DOI":"10.1212\/WNL.0000000000000741"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rigo F, Hua Y, Krainer AR, and Bennett CF. Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 2012; 199:21-25.","DOI":"10.1083\/jcb.201207087"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lowes LP, Alfano LN, Arnold WD, Shell R, Prior TW et al. Impact of age and motor function in a phase 1\/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr Neurol 2019; 98:39-45.","DOI":"10.1016\/j.pediatrneurol.2019.05.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sivaramakrishnan M, McCarthy KD, Campagne S, Huber S, Meier S et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat Commun 2017; 8:1476.","DOI":"10.1038\/s41467-017-01559-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Govoni A, Gagliardi D, Comi GP, and Corti S. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol 2018; 55:6307-6318.","DOI":"10.1007\/s12035-017-0831-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. J\u0119drzejowska M. Advances in newborn screening and presymptomatic diagnosis of spinal muscular atrophy. Degener Neurol Neuromuscul Dis 2020; 10:39-47.","DOI":"10.2147\/DNND.S246907"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dangouloff T, Vr\u0161\u010daj E, Servais L, Osredkar D, and SMA NBS World Study Group. Newborn screening programs for spinal muscular atrophy worldwide: where we stand and where to go. Neuromuscul Disord 2021; 31:574-582.","DOI":"10.1016\/j.nmd.2021.03.007"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Schorling DC, Pechmann A, and Kirschner J. Advances in treatment of spinal muscular atrophy \u2013 new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020; 7:1-13.","DOI":"10.3233\/JND-190424"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K et al. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol 2021; 74:560-566.","DOI":"10.1016\/j.jhep.2020.11.001"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Shababi M, Lorson CL, and Rudnik-Sch\u00f6neborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat 2014; 224:15-28.","DOI":"10.1111\/joa.12083"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Harada Y, Rao VK, Arya K, Kuntz NL, DiDonato CJ et al. Combination molecular therapies for type 1 spinal muscular atrophy. Muscle Nerve 2020; 62:550-554.","DOI":"10.1002\/mus.27034"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther 2019; 36:1164-1176.","DOI":"10.1007\/s12325-019-00923-8"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/69\/3.4\/69_MS6934008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T05:07:40Z","timestamp":1716008860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/69\/3.4\/69_MS6934008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":13,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms6934008","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"article-number":"MS6934008"}}